Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies
- 8 November 2016
- journal article
- Published by The Endocrine Society in Endocrinology
- Vol. 158 (1), 170-182
- https://doi.org/10.1210/en.2016-1426
Abstract
Nestorone® (NES) is a highly potent non-androgenic progestin being developed for contraception. NES is a synthetic progestin that may possess neuroprotective and myelin regenerative potential as an added health benefits. In receptor transactivation experiments, NES displayed greater potency than progesterone to transactivate the human progesterone receptor (hPR). This was confirmed by docking experiments which revealed that NES adopts the same docking position within the PR ligand-binding domain (LBD) as progesterone and forms additional stabilizing contacts between 17α-acetoxy and 16-methylene groups and PR LBD supporting its higher potency than progesterone. The analogue 13-ethyl NES also establishes similar contacts as NES with Met909, leading to comparable potency as NES. In contrast, NES is not stabilized within the human androgen receptor (hAR)-LBD leading to negligible AR transactivation. Since progesterone acts in the brain by both PR-binding and indirectly via the metabolite allopregnanolone binding to GABAA receptor (GABAAR), we investigated if NES is metabolized to 3α, 5α-tetrahydronestorone (3α, 5α-THNES) in the brain and if this metabolite could interact with GABAAR. In female mice, low concentrations of reduced NES metabolites were identified by Gas Chromatography-Mass Spectrometry in both plasma and brain. However, electrophysiological studies showed that 3α, 5α-THNES exhibited only limited activity to enhance GABAAR-evoked responses with WSS-1 cells and did not modulate synaptic GABAARs of mouse cortical neurons. Thus the inability of reduced metabolite of NES (3α, 5α-THNES) to activate GABAAR suggests that the neuroprotective and myelin regenerative effects of NES are mediated via PR binding and not via its interaction with the GABAAR.Keywords
This publication has 40 references indexed in Scilit:
- Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male ratMolecular and Cellular Endocrinology, 2010
- Clinically Relevant Progestins Regulate Neurogenic and Neuroprotective Responses in Vitro and in VivoEndocrinology, 2010
- Met909 Plays a Key Role in the Activation of the Progesterone Receptor and Also in the High Potency of 13-Ethyl ProgestinsMolecular Pharmacology, 2009
- Comparison of crystal structures of human androgen receptor ligand‐binding domain complexed with various agonists reveals molecular determinants responsible for binding affinityProtein Science, 2006
- Extrasynaptic GABAAReceptors of Thalamocortical Neurons: A Molecular Target for HypnoticsJournal of Neuroscience, 2005
- New progestagens for contraceptive useHuman Reproduction Update, 2005
- Nestorone®: a progestin with a unique pharmacological profileSteroids, 2000
- Synthesis and biological activity of a new progestogen, 16-methylene-17α-hydroxy-18-methyl-19-norpregn-4-ene-3,20-dione acetateSteroids, 2000
- The influence of an endogenous β3 subunit on recombinant GABAA receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cellsNeuropharmacology, 2000
- Modulation of the GABA A receptor by progesterone metabolitesProceedings of the Royal Society of London. B. Biological Sciences, 1987